Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Primus Pharmaceuticals
With
Prosoft Clinical
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque-type psoriasis.
Subjects with psoriasis involving 10 to 20% BSA, not including the face, scalp, groin, axillae and other intertriginous areas.
Subjects must have an IGA grade of 3 (moderate) at the Baseline Visit
You may not be if
Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis.
Other inflammatory skin disease that may confound the evaluation of the plaque psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea corporis).
Presence of pigmentation, extensive scarring, or pigmented lesions or sunburn which could interfere with the rating of efficacy parameters.
History of psoriasis unresponsive to topical treatments.
History of organ transplant requiring immunosuppression, HIV, or other immunocompromised state.
Clareo Health | A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
